Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

被引：24
|
作者：
Sikic, B. I.
Eckhardt, S. G.
Gallant, G.
Burris, H. A.
Camidge, D. R.
Colevas, A. D.
Jones, S. F.
Messersmith, W. A.
Wakelee, H. A.
Li, H.
Kaminker, P. G.
Morris, S.
Infante, J. R.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Human Genome Sci, Rockville, MD USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Colorado Denver, Aurora, CO USA
[6] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[7] Univ Colorado, Ctr Canc, Aurora, CO USA
[8] Aegera Therapeut, Montreal, PQ, Canada
[9] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3008
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors
    Morita, Sachi
    Minami, Hironobu
    Mitsuma, Ayako
    Toyoda, Masanori
    Kiyota, Naomi
    Ando, Yuichi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E427 - E434
  • [33] A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies
    Shapiro, Geoffrey I.
    Heath, Elizabeth
    Malburg, Lisa
    DeZube, Bruce
    Miles, Dale
    Keer, Harold N.
    Xu, Andrew X.
    Laeder, Theresa
    LoRusso, Patricia
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3510S - 3511S
  • [34] A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
    Herbert I. Hurwitz
    Roger B. Cohen
    J. Patrick McGovren
    Samit Hirawat
    William P. Petros
    Yutaka Natsumeda
    Tomoko Yoshinari
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 139 - 147
  • [35] A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
    Hurwitz, Herbert I.
    Cohen, Roger B.
    McGovren, J. Patrick
    Hirawat, Samit
    Petros, William P.
    Natsumeda, Yutaka
    Yoshinari, Tomoko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (01) : 139 - 147
  • [36] PHASE I STUDY OF THE SMOOTHENED (SMO) ANTAGONIST LDE225 IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD), AND ANTITUMOR ACTIVITY IN MEDULLOBLASTOMA
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Amakye, Dereck D.
    Granvil, Camille
    Shou, Yaping
    Dey, Jyotirmoy
    Buonamici, Silvia
    Dienstmann, Rodrigo
    Mita, Alain C.
    Dummer, Reinhard
    NEURO-ONCOLOGY, 2011, 13 : 87 - 88
  • [37] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
    Rosen, L. S.
    Wilding, G.
    Sweeney, C.
    Casale, D.
    Kollia, G.
    Wu, C.
    Ayers, M.
    Hill, C.
    Galbraith, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
  • [39] Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
    Leijen, Suzanne
    Middleton, Mark R.
    Tresca, Patricia
    Kraeber-Bodere, Francoise
    Dieras, Veronique
    Scheulen, Max E.
    Gupta, Avinash
    Lopez-Valverde, Vanesa
    Xu, Zhi-Xin
    Rueger, Ruediger
    Tessier, Jean J. L.
    Shochat, Eliezer
    Blotner, Steve
    Naegelen, Valerie Meresse
    Schellens, Jan H. M.
    Eberhardt, Wilfried Ernst Erich
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4794 - 4805
  • [40] Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
    Dees, E. Claire
    Cohen, Roger B.
    von Mehren, Margaret
    Stinchcombe, Thomas E.
    Liu, Hua
    Venkatakrishnan, Karthik
    Manfredi, Mark
    Fingert, Howard
    Burris, Howard A., III
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4775 - 4784
12345